Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DANAHER CORPORATION

(DHR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Danaher to Buy Aldevron for About $9.6 Billion in Cash

06/17/2021 | 09:40am EDT

By Colin Kellaher

Danaher Corp. on Thursday said it agreed to pay about $9.6 billion in cash to buy Aldevron LLC, a contract development and manufacturing organization that specializes in making biologics for the pharmaceutical and biotechnology industry.

The Washington science and technology conglomerate said it plans to fund the deal with cash on hand and/or the issuance of commercial paper.

Stockholm-based EQT AB in 2019 acquired a majority stake in Aldevron from fellow private-equity firm TA Associates, which retained a minority interest.

Danaher said Aldevron, based in Fargo, N.D., employs about 600 people and makes plasmid DNA, mRNA and proteins. The company has recently been working with Moderna Inc. to support that company's Covid-19 vaccine and other programs in its clinical pipeline.

Aldevron, which serves biotechnology and pharmaceutical customers across research, clinical and commercial applications, will operate as a standalone company and brand within Danaher's life-sciences segment.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

06-17-21 0939ET

Stocks mentioned in the article
ChangeLast1st jan.
DANAHER CORPORATION -0.05% 297.49 Delayed Quote.33.92%
EQT AB (PUBL) -0.95% 415 Delayed Quote.97.24%
All news about DANAHER CORPORATION
07/28INSIDER TRENDS : Insider at Danaher Corp Acquires Stock Via Option/Derivative Se..
MT
07/27DANAHER : Unit, Cytiva Team Up to Invest $1.5 Billion to Expand Manufacturing Ca..
MT
07/27CYTIVA : and Pall Corporation investing 1.5 billion USD over two years to meet g..
PR
07/26DANAHER : Four Sustainability Kaizens Add Up to Savings
PU
07/26DANAHER CORP /DE/ : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
07/26DANAHER : Beckman Coulter to Distribute BNP Cardiac Assay to Customers
PR
07/23DANAHER : Goldman Sachs Adjusts Danaher's Price Target to $320 from $280, Keeps ..
MT
07/23DANAHER : JPMorgan Adjusts Danaher's Price Target to $310 from $280, Keeps Overw..
MT
07/23DANAHER : Wells Fargo Adjusts Danaher's Price Target to $320 from $290, Keeps Ov..
MT
07/23DANAHER : Baird Adjusts Danaher's Price Target to $305 From $270, Reiterates Out..
MT
More news
Financials (USD)
Sales 2021 28 653 M - -
Net income 2021 6 160 M - -
Net Debt 2021 13 539 M - -
P/E ratio 2021 36,0x
Yield 2021 0,29%
Capitalization 212 B 212 B -
EV / Sales 2021 7,88x
EV / Sales 2022 7,36x
Nbr of Employees 68 000
Free-Float 74,2%
Chart DANAHER CORPORATION
Duration : Period :
Danaher Corporation Technical Analysis Chart | DHR | US2358511028 | MarketScreener
Technical analysis trends DANAHER CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Last Close Price 297,49 $
Average target price 313,63 $
Spread / Average Target 5,43%
EPS Revisions
Managers and Directors
Rainer M. Blair President, Chief Executive Officer & Director
Matthew R. McGrew Chief Financial Officer & Executive Vice President
Steven M. Rales Chairman
Jose Carlos Gutiérrez Ramos Chief Science Officer & Senior Vice President
Brian W. Ellis Senior Vice President & General Counsel
Sector and Competitors